Skip to main content

Table 2 Correlations between main classes of antibiotics consumption intensity and the rate of fluoroquinolone-resistant gram-negative bacteria

From: Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014

Classes (ATC category) Correlation
fluoroquinolone-resistant E. coli
n = 138
fluoroquinolone-resistant K. pneumoniae
n = 139
fluoroquinolone-resistant P. aeruginosa
n = 139
Levofloxacin-resistant A. baumannii
n = 131
Ciprofloxacin-resistant A. baumannii
n = 133
ra p* r p r p r p r p
All antibiotics(J01) 0.174 0.062 0.247* 0.003 0.260* 0.002 0.282* 0.001 0.194 0.055
Beta-lactams(J01C + J01D) −0.035 0.682 0.116 0.173 0.109 0.202 0.165 0.060 0.165 0.058
Beta-lactam-beta-lactamase inhibitor combinations −0.176 0.093 0.135 0.113 −0.046 0.589 −0.039 0.656 0.037 0.671
Beta-lactams excluding CBLI 0.118 0.167 0.088 0.303 0.152 0.075 0.200 0.072 0.154 0.077
Penicillins(J01C) −0.118 0.169 0.040 0.643 0.126 0.140 0.081 0.359 0.036 0.678
Penicillins excluding CBLI 0.004 0.964 0.046 0.590 0.212 0.072 0.215 0.064 0.078 0.371
Cephalosporins(J01DB + J01DC + J01DD + J01DE) −0.014 0.873 0.068 0.426 0.061 0.478 0.157 0.074 0.185 0.053
Cephalosporins excluding CBLI 0.095 0.269 0.034 0.693 0.091 0.286 0.139 0.112 0.141 0.106
3-GC(J01DD) −0.055 0.524 0.147 0.085 0.063 0.459 0.194 0.067 0.156 0.073
3GC excluding CBLI 0.093 0.276 0.131 0.125 0.109 0.203 0.246* 0.005 0.133 0.127
4-GC(J01DE) 0.037 0.671 −0.063 0.460 0.044 0.611 −0.182 0.077 −0.028 0.748
Carbapenems(J01DH) 0.129 0.131 0.242* 0.004 −0.065 0.445 −0.003 0.975 0.002 0.983
Fluoroquinolones(J01MA) 0.308** 0.000 0.291* 0.001 0.319* 0.000 0.254* 0.003 0.159 0.068
Ciprofloxacin (J01MA02) −0.014 0.869 0.075 0.383 0.054 0.532 −0.021 0.811 0.077 0.376
Levofloxacin (J01MA12) 0.252* 0.003 0.260* 0.002 0.377* 0.000 0.336* 0.000 0.157 0.072
Moxifloxacin (J01MA14) 0.131 0.127 0.093 0.278 −0.200 0.088 −0.192 0.081 −0.014 0.875
  1. ATC Anatomic Therapeutic Chemical; CBLI combinations with beta-lactamase inhibitors; 3-GC the third generation cephalosporins; 4-GC the fourth generation cephalosporins.